Clinical heterogeneity of adhalin deficiency

Lucia Morandi, Rita Barresi, Claudia Di Blasi, Daniel Jung, Yoshihide Sunada, Valeria Confalonieri, Federica Dworzak, Renato Mantegazza, Carlo Antozzi, Laura Jarre, Antonella Pini, Giuseppe Gobbi, Carlo Bianchi, Ferdinando Cornelio, Kevin P. Campbell, Marina Mora

Research output: Contribution to journalArticlepeer-review


We report adhalin deficiency in 8 patients with clinically diagnosed muscular dystrophy, dystrophic histopathological features, high plasma creatine kinase levels, normal expression of dystrophin, and marked variability of symptoms. Although the distribution of hyposthenia was similar in all 8 patients and predominantly involved muscles in the pelvic girdle, age at onset and rate of disease progression were highly variable: In 2 patients onset, at ages 24 and 25, was later than has been previously observed. We found no apparent relation between disease severity and the quantity of adhalin expressed. Two kinds of myopathy with adhalin deficiency have been reported: one caused by a mutation in the adhalin gene on chromosome 17 (primary adhalinopathy) and the other linked to chromosome 13. The product of the gene on chromosome 13 is probably associated with adhalin and its deficiency results in secondary adhalinopathy. The severity of clinical phenotypes in these adhalinopathies seems to relate more to the kind and site of the mutations than to the residual amount of the protein. We also detected a variable reduction in the laminin β1 subunit by immunohistochemistry in most patients, confirming that this is commonly associated with adhalin deficiency.

Original languageEnglish
Pages (from-to)196-202
Number of pages7
JournalAnnals of Neurology
Issue number2
Publication statusPublished - 1996

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Clinical heterogeneity of adhalin deficiency'. Together they form a unique fingerprint.

Cite this